share_log

Biomerica | 8-K: Current report

Biomerica | 8-K: Current report

Biomerica | 8-K：重大事件
美股sec公告 ·  05/11 05:19
牛牛AI助理已提取核心訊息
On May 10, 2024, Biomerica, Inc. announced the entry into an At Market Issuance Sales Agreement with EF Hutton LLC and R.F. Lafferty & Co., Inc., enabling the company to offer and sell up to $5.5 million of its common stock. The same day, Biomerica filed a prospectus supplement with the SEC for the sale of these shares. The Placement Shares are registered under the Securities Act of 1933, following a Registration Statement filed on September 28, 2023, and declared effective on September 29, 2023. The company may sell the shares at market offerings, with the Sales Agents acting as sales agents. Biomerica has the discretion to suspend offers or terminate the Sales Agreement and intends to use the net proceeds for general corporate purposes. Additionally, on May 7, 2024, Biomerica received a notice from Nasdaq due to the company's stock price falling below the minimum bid price requirement for 32 consecutive business days. The company has until November 4, 2024, to regain compliance with Nasdaq's minimum bid price rule.
On May 10, 2024, Biomerica, Inc. announced the entry into an At Market Issuance Sales Agreement with EF Hutton LLC and R.F. Lafferty & Co., Inc., enabling the company to offer and sell up to $5.5 million of its common stock. The same day, Biomerica filed a prospectus supplement with the SEC for the sale of these shares. The Placement Shares are registered under the Securities Act of 1933, following a Registration Statement filed on September 28, 2023, and declared effective on September 29, 2023. The company may sell the shares at market offerings, with the Sales Agents acting as sales agents. Biomerica has the discretion to suspend offers or terminate the Sales Agreement and intends to use the net proceeds for general corporate purposes. Additionally, on May 7, 2024, Biomerica received a notice from Nasdaq due to the company's stock price falling below the minimum bid price requirement for 32 consecutive business days. The company has until November 4, 2024, to regain compliance with Nasdaq's minimum bid price rule.
2024年5月10日，Biomerica, Inc. 宣佈與EF Hutton LLC和R.F. Lafferty & Co., Inc. 簽訂了市面發行銷售協議，使該公司能夠發行和出售高達550萬美元的普通股。同一天，Biomerica向美國證券交易委員會提交了出售這些股票的招股說明書補充文件。配售股份根據1933年的證券法進行註冊，此前於2023年9月28日提交了註冊聲明，並於2023年9月29日宣佈生效。公司可以在市場發行時出售股票，銷售代理充當銷售代理。Biomerica有權自行決定暫停要約或終止銷售協議，並打算將淨收益用於一般公司用途。此外，2024年5月7日，Biomerica收到了納斯達克的通知，原因是該公司的股價連續32個工作日跌破最低出價要求。該公司必須在2024年11月4日之前重新遵守納斯達克的最低出價規則。
2024年5月10日，Biomerica, Inc. 宣佈與EF Hutton LLC和R.F. Lafferty & Co., Inc. 簽訂了市面發行銷售協議，使該公司能夠發行和出售高達550萬美元的普通股。同一天，Biomerica向美國證券交易委員會提交了出售這些股票的招股說明書補充文件。配售股份根據1933年的證券法進行註冊，此前於2023年9月28日提交了註冊聲明，並於2023年9月29日宣佈生效。公司可以在市場發行時出售股票，銷售代理充當銷售代理。Biomerica有權自行決定暫停要約或終止銷售協議，並打算將淨收益用於一般公司用途。此外，2024年5月7日，Biomerica收到了納斯達克的通知，原因是該公司的股價連續32個工作日跌破最低出價要求。該公司必須在2024年11月4日之前重新遵守納斯達克的最低出價規則。
有用
沒用

該公告為獨立文件：

獨立文件1

獨立文件2

獨立文件3

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。